Brutalist Biotech

• The next generation of pulsed field ablation takes the stage at HRS annual meeting (2d)
• ALX Oncology doubles down on lead CD47 inhibitor after asset fails two midstage cancer trials (2d)
• HHS reverses course, says long-running women’s health study will retain funding (2d)
• Study illustrates pros, cons in AI readings of 3D mammography scans (2d)
• M&A remains ‘top priority’ for Big Pharmas in the face of tariff threat (2d)
• FDA puts Vyne in a twist, slapping hold on psoriasis trial over testicular toxicity concerns (2d)
• Caribou cuts 32% of staff, further purges pipeline to focus on oncology CAR-T prospects (3d)
• Chutes & Ladders—Galapagos CEO eyes exit as spinout names leader (3d)
• Ex-FDA leader joins new initiative designed to fight ‘unfortunate reality’ of vaccine landscape (3d)
• Boston Scientific plans to make ground despite $200M in tariff headwinds (3d)
• Lowering blood pressure reduces dementia risk in patients with hypertension, large China trial reveals (3d)
• Bioxodes halts phase 2 stroke trial after successful interim review, plots registrational study (3d)
• Mosaic adds to cancer combo pattern by licensing 2 clinical-stage drugs from Astex (3d)
• Sanofi’s oral TNF inhibitor misses mark in phase 2 psoriasis trial, prompting focus on combos (3d)
• Tariffs will make financial case for pharma M&A ‘more difficult,’ says Roche CEO (3d)
• Versant's Granite Bio unveils with $100M for new autoimmune disease antibodies (4d)
• Nonprofit Cultivarium nets $10M to build tools for researchers studying fungi and archaea (4d)
• Bayer tunes precision oncology development using ConcertAI’s database (4d)
• Trump administration cuts down funding for largest women’s health research initiative in US (4d)
• Intuitive posts strong first-quarter earnings as tariffs set to squeeze margins (4d)

• Biohaven stock slides on withdrawal of European marketing application (2d)
• Gilead leans on HIV drugs as oncology sales slow (2d)
• Halozyme sues Merck; FDA blames cuts for Vanda delay (2d)
• Caribou, in reversal, scraps autoimmune cell therapy and cuts staff (2d)
• Bristol Myers says schizophrenia drug launch ‘off to a solid start’ (3d)
• Merck takes $200M tariff hit, trimming its gross profits (3d)
• Sanofi stays course amid tariff turmoil (3d)
• Versant startup Granite debuts with $100M and two immune drugs (3d)
• Etiome, a new Flagship startup, looks to catch disease before it strikes (3d)
• German antibody maker valued at $1.6B in blank-check merger (4d)
• Bristol Myers’ prized schizophrenia drug stumbles in testing (4d)
• [Podcast] Behind the Breakthroughs: How Almac Powers Clinical Trial Success with Care (4d)
• Roche looks to a Flagship startup in search of new immune drugs (4d)
• Roche, answering tariff threat, pledges $50B to US drug production (5d)
• Akeso claims another PD-1/VEGF win; FDA requests more data from Novavax (5d)
• The Trump administration is remaking HHS. Track the changes here. (5d)
• Arkansas passes law banning PBMs from owning pharmacies (5d)
• Former Neumora CEO to lead Galapagos spinout (5d)
• Novo says it’s submitted obesity pill for FDA approval (6d)
• Enhertu combo tops standard drugs in first-line HER2 breast cancer (6d)

• J&J reports durability data for bladder cancer 'pretzel' drug (1d)
• Earnings season is upon us; Makary on rare disease; Startup is first to inject CRISPR in the brain; and more (1d)
• FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill (2d)
• AbbVie eyes $10B US expansion amid sector-specific tariff threat (2d)
• Amgen invests $900M to expand Ohio biomanufacturing (2d)
• Compounding pharmacies dealt blow in semaglutide shortage case (2d)
• RFK Jr. touts program testing ways to pay for sickle cell care (2d)
• Akeso reveals survival data for Keytruda-beating cancer drug (2d)
• ALX Oncology reports Phase 2 failures for CD47 drug combo with Keytruda (2d)
• Alis Biosciences to press struggling biotechs during downturn (2d)
• Merck cuts several Phase 2 programs; Vyne’s Phase 1b psoriasis trial put on clinical hold (2d)
• AbbVie Q1 earnings: Immunology still a powerhouse as Skyrizi, Rinvoq hit $5B combined (2d)
• Paul Stoffels on retiring from Galapagos; Boehringer Ingelheim switches up leadership (2d)
• Merck KGaA closes in on SpringWorks deal at $3.5B price point (2d)
• Gilead's strong HIV business balances out low Covid and cancer drug sales (3d)
• Caribou lays off 32% of staff, cuts lupus program (3d)
• Merck is well-stocked on Keytruda as pharma tariffs loom, CEO says (3d)
• Biosimilar launch challenges remain, report finds (3d)
• Drugmakers prepare for manageable tariff hit to business, earnings (3d)
• Cassidy urges major reforms to 340B drug discount program (3d)

• Caribou Changes Course Again, Lays Off 32% of Workforce (2d)
• Fact or Fiction? Unpacking FDA Commissioner Marty Makary’s First Interviews (2d)
• AbbVie Lambasts Trump’s Drug Pricing Proposal, Deflects Tariff Concerns (2d)
• Vyne Crashes After Safety Signal in Dogs Puts Hold on Clinical Trial of Plaque Psoriasis (2d)
• SpringWorks Surges on Potential $3.5B Merck KGaA Buyout (2d)
• Judge Rules Against Semaglutide Compounders After Shortage Ruled Over (2d)
• Gilead’s PrEP Launch Full Speed Ahead, Despite Macro Pressures on HIV Space (2d)
• Merck, Boehringer Ingelheim, More to Present Key Data at AACR ‘25 (2d)
• BMS Reports Mixed Earnings as Growth Portfolio Makes Up for Generic Pressure (3d)
• Tariff Uncertainty Reigns Over Q1 Earnings, With Merck Taking $200M Blow So Far (3d)
• Novartis-, Sanofi-Backed Granite Brings $100M to Compete in Crowded I&I Space (3d)
• Economic Challenges, Strategic Investments: Reshaping the Women's Health Landscape (3d)
• Etiome Steps Out of Stealth with $50M to Address Disease At The 'Silent Stage' (3d)
• After Missed Decision Deadline, Novavax Says COVID-19 Shot ‘Approvable’ (3d)
• Vanda Escalates Vendetta Against FDA, Blasts ‘Bureaucrats’ For Delaying Stomach Drug (3d)
• Sales Of Merck’s 4-Way Measles Vaccine Take Hit as US Dips Into Stockpile (3d)
• Guessing Game: Former HHS Workers’ Next Stops Unclear (3d)
• Massive Investment in US Manufacturing Triggers Wave of Career Opportunities (3d)
• Roche in ‘Very, Very Good Position’ to Weather Trump Tariffs, But M&A May Suffer (3d)
• Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage (3d)

Bio IT World

• Advancing Precision Medicine with Ethical AI and Standardized Data (2d)
• Tech Veteran Chris Dwan Challenges Life Sciences to Build Infrastructure, Businesses Strategically (4d)
• AI in Drug Development: Promise and Pitfalls (5d)
• Insilico’s Alex Zhavoronkov Highlights Generative AI's Impact on Drug Discovery and Aging Research (1w)
• AI Continues to Make Strides on Therapeutics and Research Progress (2w)
• Derek Lowe on AI in Drug Discovery: Between Hype and Hope (2w)
• Large Language Model Predicts, as Well as Explains, Molecular Properties (2w)
• AI Struggles and Opportunities in Life Sciences and Healthcare (3w)
• Researchers Transform Gut Bacteria into ‘Little Pharmacists’ (3w)
• Bio-IT Community Honors New Products from Boulder BioComputing, Dantech Corp, The Hyve, Velsera (3w)
• Evaluating the Benefits and Risks of Weight Loss Drugs (3w)
• Large Genetic Study Further Untangles the Height-Health Connection (4w)
• Bio-IT World Best of Show Finalists Named (1mo)
• Pistoia Alliance Reducing Carbon Footprint, Thermo Fisher Next-Gen Hybrid Capture Assay, More (1mo)
• Follow the Money: Gene Editing Therapeutics, Breast Cancer AI Predictive Platform, More (1mo)
• Elsevier Launches AI Search, Summary, Comparison Tool for ScienceDirect (1mo)
• Bio-IT World Names Innovative Practices Winners (1mo)
• Flatiron Health Enables Patient-Level Data Sharing Across National Borders (1mo)
• ‘Therapeutic Blood Clots’ Could Remedy Cartilage Loss from Osteoarthritis (1mo)
• New Healthcare Security Benchmark Highlights Key Investment Priorities and Risks (1mo)

• U.S. health officials inject new uncertainty into approval process for Covid boosters (1h)
• ‘Fight for your science’: Researchers urged to speak out at AACR (4h)
• Taking science’s temperature at the annual AACR meeting (1d)
• STAT readers on the animal wellness industry, drug price floors, and more (1d)
• Rural health study is told it’s losing federal funds, and other major heart studies are worried (2d)
• Sutter Health will pay nearly $230 million to settle class-action antitrust case (2d)
• NIH announces six new acting institute directors, many of them filling posts of ousted predecessors (2d)
• Luigi Mangione pleads not guilty to federal murder charge in killing of UnitedHealthcare’s CEO (2d)
• Up and down the ladder: The latest comings and goings (2d)
• Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda (2d)
• Vanderbilt medical center warns suppliers not to raise prices due to tariffs, or they may not get paid (2d)
• Approaching 100 days of Trump (2d)
• We’re reading about the FDA and revolving doors, a Novo win over compounders, and more (2d)
• Belgian antitrust regulator fines three companies $12.8 million over pharmacy displays (2d)
• Court ruling opens door to FDA action against Ozempic compounders (2d)
• Struggling lobbyists, panicked clients: D.C. comes to grips with Trump’s second term (2d)
• With the FDA in turmoil, the ‘revolving door’ with industry is spinning faster (2d)
• NIH cuts will set back research into the rare disease that has terrorized my family (2d)
• Trump’s first 100 days, seen through 5 lives: Grants terminated. Dreams crushed. Futures in the balance (2d)
• Women’s Health Initiative to receive NIH funding after all (3d)

• NHS Wales Pilots Paige AI Tool to Triage Cancer Cases (3d)
• Novotech Report: Over 800 Global IPF Trials Since 2020, Led by Asia-Pacific (3d)
• Immunai and Parker Institute to Build Largest Single-Cell Dataset for Real-World Immunotherapy Research (3d)
• Potato Lands $4.5M to Automate Lab Work with AI and Robots (3d)
• Tempus, AstraZeneca, and Pathos Partner to Build Oncology Foundation Model Using Multimodal Data (4d)
• GeneDx to Acquire Fabric Genomics to Enable AI-Powered, Decentralized Genome Interpretation (2w)
• Elix and PRISM BioLab Partner to Tackle Hard-to-Drug Protein Targets with AI (2w)
• Netherlands Outlines 2040 Biotech Vision, Emphasizing Tools, Commercialization, and Regulatory Reform (2w)
• Sanger and PacBio Launch Long-Read Effort to Decode Immune Gene Activity (2w)
• Finalists Announced for $10M Coller Dolittle Challenge on AI-Powered Interspecies Communication (2w)
• BayPine Acquires Clinical Trial Network CenExel, Plans Digital Infrastructure and AI Expansion (2w)
• Biostate AI to Develop Predictive Models for Multiple Sclerosis Using Transcriptomic Data (2w)
• Scotland Launches ‘AI Discovery’ to Foster DeepTech AI Startups for NHS Healthcare Innovation (2w)
• FDA Plan to Replace Animal Testing with AI Models and Human-Based Methods in Drug Evaluation Shift (2w)
• Ingenix.ai Secures €9M to Advance Multimodal AI Foundation Model for Simulating Clinical Trials (2w)
• Recursion and Enamine Release AI-Curated Screening Libraries Targeting 100 Challenging Drug Targets (3w)
• First Genetically Engineered Dire Wolf-Like Animals Born (3w)
• Recursion Doses First Patient in Phase 1 Trial of AI-Designed MALT1 Inhibitor (3w)
• IQVIA Introduces a Compact Medical Reasoning LLM Outscoring Larger Models (3w)
• Verge Genomics Reports Digital Biomarkers May Track Early ALS Progression in Pre-Treatment Trial Phase (3w)

• The past, present, and future of genome sequencing (2d)
• AI in biotech today, and how it will impact the industry tomorrow (2d)
• 21 UK biotech companies you should know about (3d)
• The emergence of BTK inhibitors in multiple sclerosis treatment: Companies close in on approval (4d)
• Tariffs and trade war: A guide for expanding biotech business internationally (5d)
• Tariffs and trade war: A guide for expanding biotech business internationally (5d)
• Seven biotechs to watch in the hepatitis B space (5d)
• Biomaterials in construction: meet the startups reinventing our buildings (1w)
• HIV innovation: Six companies developing new treatments in 2025 (2w)
• Beyond CRISPR: Brink Therapeutics raises $4 million with engineered recombinases (2w)
• The AI race in biotech: Is Europe falling behind the US and China? (2w)
• Metabolomics: The study of biology’s dark matter (2w)
• Basel: What’s behind the success of one of Europe’s leading biotech hubs? (2w)
• How nanobodies will revolutionize immunotherapy (2w)
• The biotech job market in 2025: Still in survival mode? (3w)
• Cystic fibrosis: is the next blockbuster a gene therapy? (3w)
• 13 anti-aging startups on a mission to extend lives (3w)
• Will tRNA therapy be the next big thing in genetic disease treatment? (3w)
• Meeting the global demand for cell therapies: scaling with smart manufacturing (3w)
• Developing drugs from outer space: Exobiosphere raises €2 million (3w)

• StockWatch: Tools Giants Foresee Revenue Impacts from Tariffs, Job Cuts (4h)
• Navigating Biotech’s New Normal, AI to Engineer Cas9 Enzymes, and Sequencing Generations (2d)
• BioSkryb and Tecan Introduce Single-Cell Multiomics Workflow (2d)
• AACR 2025 Chairs Identify Themes and Highlights From the Conference (2d)
• Sugar Swap Leads to Sweet Spot in Creating “Super Stem Cells” (2d)
• New Podcast, The ImmunoVerse, Highlights Immunotherapy Research (3d)
• Blocking Erythropoietin Signaling Renders Mouse Liver Tumors Sensitive to Anti-PD-1 Therapy (3d)
• Blocking Erythropoietin Signaling in Mice Converts Liver Tumors into Immunotherapy Responders (3d)
• AACR 2025: Professional Awards Acknowledge Contributions to Cancer Research and Treatment (3d)
• Signal Alert: Startup Seeks Community Funders for AAV Immuno-Gene Therapy (3d)
• Bioprinting Technique Brings Vascularized Tissue One Step Closer (3d)
• FUJIFILM Diosynth Biotechnologies and Regeneron Sign 10-year, $3+ Billion U.S. Manufacturing Deal (3d)
• Immunai and Parker Institute to Build Massive Cancer Single-Cell Dataset (3d)
• Revvity to Unveil VivoJect™ Image-guided Injection System at AACR (3d)
• Multi-Platform Sequencing Study of Four Generations Sheds Light on Mutation Rates (4d)
• Psychedelics May Reverse Effects of Neuroimmune Interactions That Drive Fear Responses (4d)
• Researchers Test Minimal Helper Plasmids for AAV Production (4d)
• AI and Automation Skills Critical for Future Biopharma Engineers (4d)
• Assays Improve Gene Therapy Production (4d)
• Watchmaker Genomics and Revvity Team to Automate and Streamline NGS Library Preparation (4d)

• Healer, Mentor and Leader (6h)
• Treatment With HT-KIT Shows Early Preclinical Activity in GIST Models (6h)
• FDA OKs Investigational New Drug Application for VS-7375 in Solid Tumors (1d)
• Crafting an Individual Treatment Plan for Patients With Prostate Cancer (1d)
• Commitment to Patients Is Driven by a Lasting Promise (2d)
• Understanding the FDA Imfinzi Combo Approval for Bladder Cancer Care (2d)
• New Options for ER+ Breast Cancer Spotlighted at Patient Event (2d)
• A Digital Detox for the Soul with Lynch Syndrome (2d)
• Decipher Prostate Test Now Available for Metastatic Prostate Cancer (2d)
• Evorpacept With Keytruda Did Not Elicit Responses in Head and Neck Cancer (2d)
• ctDNA Clearance Linked to Improved Survival in Oncogene-Driven NSCLC (2d)
• The Fearless Patient Advocate (3d)
• Working to Address Unmet Medical Needs in MPNs (3d)
• First Patient Enrolled in ARID II Trial for Prostate Cancer Treatment (3d)
• Taking Charge of My Care and Advocacy Following a Cancer Diagnosis (3d)
• FDA Approves Penpulimab-kcqx For Nasopharyngeal Carcinoma (3d)
• Dose-Limiting Toxicity Observation Phase Completed in CRS Trial for Lymphoma (3d)
• Early Symptoms, Risk Factors and Treatment Options for Esophageal Cancer (3d)
• Optune Lua Receives CE Mark in Europe for Metastatic NSCLC (4d)
• How to Best Navigate a Diagnosis of Lung and Head and Neck Cancer (4d)

Contract Pharma*

• FDA Approves Akeso’s Penpulimab for Nasopharyngeal Carcinoma (2d)
• CPTx Appoints McDavid Stilwell as Chief Financial Officer (3d)
• BMS Pays Evotec $75M for Molecular Glue Research Progress (3d)
• Mosaic Therapeutics In-Licenses Oncology Programs from Astex (3d)
• CN Bio & Pharmaron Partner to Advance Organ-on-a-Chip Drug Discovery (3d)
• Hansa Biopharma Appoints New CEO (3d)
• Debiopharm & Oncodesign Partner on Cancer Imaging Tech (3d)
• Ferring Pharmaceuticals’ Drug Product Manufacturing Hub in NJ Approved by FDA (3d)
• Integer Announces CEO Succession Plan (3d)
• PCI Pharma Services to Acquire Ajinomoto Althea (3d)
• EVERSANA Expands Distribution Center with Cold Chain Capabilities and AI-Powered Robotics (3d)
• Asahi Kasei Taps Ken Shinomiya as Leader of Its Healthcare Sector (3d)
• Why You Should Choose a Boutique CDMO (4d)
• Galapagos Appoints Founding CEO of Newly Created SpinCo (4d)
• Repertoire & Genentech Partner on Autoimmune T-Cell Therapies (4d)
• Zealand Pharma appoints Utpal Singh as Chief Scientific Officer (4d)
• Antag Therapeutics Adds New Leadership (4d)
• Cell Therapy at Scale: Digitalizing Manufacturing for Compliance and Efficiency (5d)
• Cell Therapy at Scale: Digitalizing Manufacturing for Compliance and Efficiency (5d)
• Suanfarma Taps Pere Mañé Godina as CEO (5d)

• Acoramidis approved for heart condition treatment (2d)
• Genomics study launches to optimise childhood cancer care in Ireland (3d)
• UCL researchers launch congenital muscular dystrophy research programme (4d)
• Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine (5d)
• FDA approves Click’s digital therapeutic for episodic migraine (1w)
• Leqembi approved as first treatment to slow early Alzheimer’s progression (2w)
• Pepaxti shows effectiveness in heavily pretreated multiple myeloma patients (2w)
• New data reinforce daratumumab as standard of care for multiple myeloma (2w)
• Global data highlights effectiveness of romosozumab (2w)
• UK clinical trials regulations signed into law (2w)
• New test prototype for monitoring MGUS patients funded (2w)
• First treatment for common bladder cancer recommended by NICE (2w)
• Lab-grown lung cancer cells shows potential to revolutionise treatment (2w)
• NHS launches spring COVID-19 booster campaign (3w)
• SkyCell and Microsoft partner to improve pharma supply chains (3w)
• MHRA approves prostate cancer imaging agent trofolastat (3w)
• Endlyz Therapeutics emerges with pipeline for Parkinson’s disease (3w)
• SMC approves bimekizumab for hidradenitis suppurativa treatment (3w)
• European Commission approves ustekinumab for paediatric Crohn’s disease (3w)
• Elekta and Azra AI partner to advance cancer registry operations with AI (3w)

• Bringing Patient Data to the Frontlines: Why Interoperability Must Include EMS (10h)
• Hospitals Are Freezing M&A Deals as Federal Policies Rattle Industry (10h)
• Novo Nordisk Notches a Court Win Against Wegovy and Ozempic Compounders (11h)
• The Silent Mental Health Crisis of Climate Change (11h)
• Orchestra BioMed’s Hypertension Device Wins FDA Breakthrough Designation (2d)
• CRISPR Biotech Caribou Trims Pipeline and Cuts 32% of Staff to Focus on Two Cancer Cell Therapies (2d)
• Agentic AI and the Architecture of Healthcare Transformation (2d)
• 5 Major Trends Emerging in Healthcare Benefits in 2025 (2d)
• Community-Driven Digital Solutions Can Transform Addiction Treatment and Ease the Burden on the Healthcare System (2d)
• Nourish Lands $70M to Fight Chronic Disease with Nutrition Care (3d)
• Trial Data Shows ‘IUD for Men’ Is Effective for 2 Years (3d)
• Aiming for Earlier Intervention, Flagship Startup Etiome Emerges to Define ‘Biostages’ of Disease (3d)
• MedCity Pivot: What if Pancreatic Cancer Became a Chronic Disease? (3d)
• How Health Insurers Are Embracing Technology to Serve Real People (3d)
• Advancing Patient & Planet Health Through Proper Healthcare Waste Management (3d)
• The Top Surgical Instruments Needed for Extractions (3d)
• There’s a Gap Between Healthcare Leaders’ AI Confidence and Their Ability to Scale (4d)
• World Class Health Secures $10M for Global Centers of Excellence Network (4d)
• Bristol Myers Squibb Schizophrenia Drug Fails Pivotal Test as an Add-On to Antipsychotics (4d)
• Improving Patient Trust with Digital Communication (4d)

• US halts funding for new COVID-19 vaccines (2d)
• OxyVinyls will contribute to the $600 million settlement in the East Palestine train derailment case (2d)
• Grove Biopharma launches to develop therapeutic protein-like polymers (2d)
• Periodic Graphics: Permanent magnets explained (2d)
• A new way to recycle waste silicones (2d)
• Nylon maker Ascend files for bankruptcy (3d)
• Dow plans deep cuts amid poor economy (3d)
• More hurt for European chemical firms (3d)
• How to read science news (3d)
• US rule targets federal workers who don't advance Trump's policies (3d)
• Oxy buys direct air capture firm Holocene (3d)
• Flagship Pioneering launches start-up to suss out disease-state biomarkers (3d)
• FDA eyes phaseout of petroleum-based food dyes (4d)
• Business briefing for April 28 (4d)
• Polymer coatings may damage iron artifacts (4d)
• NSF eliminates external advisory committees (4d)
• Ill-fitting lab coats raise safety and inclusivity concerns (4d)
• Lanthanide orbitals spring a reaction surprise (4d)
• Pushing boundaries and solving global challenges at ACS Spring 2025 (4d)
• And the XPrize Carbon Removal winners are . . . (4d)

The Pharma Letter*

• The week in pharma: action, reaction and insight – week to April 25 (13h)
• Amgen announces $900 million production investment (1d)
• MHRA nod for Bayer’s Beyonttra for ATTR-CM (1d)
• New medicines recommended for approval by CHMP in April 2025 (1d)
• AbbVie arrows upwards on upgraded earnings estimate (2d)
• New EC nod for J&J’s Tremfya (2d)
• Guardant Health and Pfizer team up (2d)
• LTZ bags $40 million as it sends first myeloid engager into clinic (2d)
• Industry-backed study highlights value of antibiotic R&D incentive (2d)
• Convatec to launch nitric oxide product as analysts highlight resilience (2d)
• Halozyme files lawsuit against Merck over SC Keytruda (2d)
• Revenues flat at Gilead as HIV strength offsets oncology struggle (2d)
• $100 million gives Granite solid foundation for autoimmune work (2d)
• FDA approves penpulimab-kcqx for NP carcinoma (2d)
• FDA declines itolizumab accelerated approval, says Equillium (2d)
• FDA declines itolizumab accelerated approval, says Equillium (2d)
• Dark Blue Therapeutics (2d)
• Avidicure starts with $50 million for novel cancer antibody work (3d)
• Merck & Co beats estimates but lowers earnings outlook (3d)
• Samsung Bioepis’ latest Biosimilar Market Report (3d)

• SunRISe-1 Cohort 4: Promising TAR-200 Outcomes in Papillary NMIBC (4h)
• Bladder Cancer Takes Center Stage With Breakthrough Advancements at AUA 2025 (7h)
• KEYNOTE-689 Trial of Pembrolizumab Shows Promising EFS in LA-HNSCC (7h)
• Disitamab Vedotin Plus BCG Shows Promise in HER2-Expressing, High-Risk NMIBC (8h)
• Nogapendekin Alfa Inbakicept Impresses With Stable CR and Cystectomy-Avoidance Rate in BCG-Unresponsive Bladder Carcinoma (8h)
• The Targeted Pulse: AI Cancer Diagnosis, Breast Cancer Treatment Updates, and More (13h)
• High CR Rate with Cretostimogene for BCG-Failed Bladder Cancer (1d)
• TAR-200 Shows Durable Response in BCG-Unresponsive NMIBC: SunRISe-1 Cohort 2 (1d)
• Predicting Cretostimogene Grenadenorepvec Response With Urinary Genomics (1d)
• EVP With Consolidative Surgery Yields Promising Outcomes in Bladder Cancer (1d)
• Ropeginterferon Alfa Shows Disease-Modifying Potential in Polycythemia Vera (2d)
• Hope Within Reach: Expanding Access to Life-Saving Blood Cancer Therapies (2d)
• ClarityDX Prostate Utility Trial Enrolls First Patient (2d)
• Why Are Young Adults Getting More Pancreatic & Colon Cancer? (2d)
• FDA Greenlights VS-7375 Study for Tough-to-Treat KRAS G12D Tumors (2d)
• Positive Outcomes Confirmed for Frontline ICI Use in Metastatic CRC (2d)
• Assessing Risk for JAK Inhibitor Selection in Myelofibrosis (2d)
• Optimizing CAR T-Cell Therapy Prep in Multiple Myeloma After Relapse (3d)
• Cabozantinib/Nivolumab Efficacy, Safety Considered for Metastatic RCC (3d)
• FDA Oks Penpulimab for First-Line Non-Keratinizing Nasopharyngeal Carcinoma (3d)

• Analyst predicts trouble ahead for GN: Trade war could derail transformation (2d)
• SSI Diagnostica increases US footprint with another acquisition (2d)
• More obesity companies want to compete on healthy weight loss and solving "ethical challenge" (2d)
• Bristol Myers Squibb fails in phase 3 trial of schizophrenia drug (2d)
• Good news for Novo in the US: Compounding pharmacies to stop sales of Wegovy and Ozempic copies (2d)
• Analyst predicts tablets will take a large share of the future obesity market: "The trend is definitely towards oral" (2d)
• MSD's Q1 figures show growth and reveal tariff impact (2d)
• Eli Lilly intensifies legal battle against copycat makers (2d)
• Fujifilm Diosynth Biotechnologies COO sees business advantage in geopolitical storm (2d)
• Sanofi's earnings soar on growing demand for blockbuster drug (2d)
• Zealand Pharma chief has more confidence in Novo Nordisk's weight-loss tablet over Eli Lilly's (3d)
• Criticism after overwhelming opposition to Bavarian exec's salary: "Tend to forget who owns them" (3d)
• Zealand Pharma announces first patient enrolled in new study with "crown jewel" (3d)
• Mass layoffs at FDA now impacting biotech companies (3d)
• ALK's tree pollen tablet approved for treatment of children in Europe (3d)
• Roche beats Q1 expectations – full-year guidance is maintained (3d)
• Zealand Pharma hires science chief from Eli Lilly (3d)
• Boston Scientific upgrades outlook after strong first quarter (3d)
• Pharma chiefs call on EU to match US drug prices (3d)
• Second crash in three years: Leo Pharma's reputation hit hard by repeated layoff rounds (3d)

• What's Going On In Water Droplets (2d)
• A New Glioblastoma Treatment (3d)
• Streptomycin For Metastatic Cancer (5d)
• The End of Disease (6d)
• You Can Probably Smell That Planet From Here (1w)
• Proton Pump Inhibitors Do More Than You Think (2w)
• Entropy, Enthalpy, and Hydrophobicity (2w)
• The Continuing Crisis, Part XII: Behold RFK Jr.'s FDA (2w)
• RNA Motifs Coming Into Focus (2w)
• Pharmaceutical Tariffs: The What and the How (3w)
• Metallic Flatland (3w)
• The Continuing Crisis, Part XI: Feral Children, Breaking Things (3w)
• Methyl Groups Will Always Be Magic (3w)
• Predicting Picky Protein Interactions (3w)
• The Continuing Crisis, Part X: Reductions in Force, Gains in Centralized Power (4w)
• A New Pan-Coronovirus Protease Inhibitor Possibility (4w)
• Pain Continues to Be a Pain (1mo)
• Alkanes on Mars (1mo)
• Starving Cancer Cells Where They Live (1mo)
• Evolving the Ability to Evolve (1mo)

• Ozempic patient blinded by NAION sues Novo Nordisk (2d)
• Akeso PD-1 inhibitor cleared as Keytruda challenger advances (2d)
• AbbVie files fast-acting Botox successor in US (2d)
• Granite Bio makes $100m debut, and other bio financings (2d)
• MSD has gauged its financial hit from Trump tariffs (2d)
• Merck puts a price on its SpringWorks takeover bid (2d)
• Irish study promises to revolutionise childhood cancer care (3d)
• Can Bioxodes end the dearth of haemorrhagic stroke drugs? (3d)
• Roche seeking talks with the US on tariff exemptions (3d)
• AstraZeneca joins Tempus, Pathos in cancer AI project (3d)
• UK's HIV response is 'failing women' (3d)
• Roche gets EU okay for chest pain algorithm (4d)
• Axtria unveils transformational agentic AI platform for life sciences (4d)
• First drug for rare disease APDS cleared for NHS use (4d)
• Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal (4d)
• Has trial result burst BMS' Cobenfy bubble? (4d)
• Senior FDA resignations gut drug advertising function (4d)
• Data readout puts J&J's bladder cancer drug back on track (5d)
• Sky Labs' smart ring tops Apple Watch in AFib comparison (5d)
• Roche joins the pharma firms planning big US investments (5d)

• Partners sign deal to build largest multimodal oncology foundation model (2d)
• This week in drug discovery (21-25 April) (2d)
• UMass joins Phase II trial for multiple sclerosis (2d)
• AACR data shows promise for patients with solid tumour types (2d)
• AI in drug discovery: Separating hype from reality, and what does it hold for CROs? (2d)
• Podcast: Where are scientists making waves in drug discovery? (3d)
• Where are scientists making waves in drug discovery? (3d)
• Roche reveals plans to invest $50 billion in the US (3d)
• Webinar: How can 3D cardiac microtissue models advance drug screening? (3d)
• Medicus extends Phase II study in nodular basal cell carcinoma (3d)
• The drug discovery challenges facing endometriosis (3d)
• Ascentage celebrates inclusion in Chinese oncology guidelines (4d)
• Phase II trial starts for CAR-T therapy in T-cell lymphoma (4d)
• Lilly’s oral GLP-1 first to complete a Phase III trial (4d)
• Teaming up to tackle global health crises: Fibrosis (4d)
• Register now: Learn to navigate AI-driven drug discovery (4d)
• New DDW Highlights podcast: 22 April 2025 (5d)
• DDW Highlights: 22 April 2025 (5d)
• FDA grants label expansion for Cushing’s disease treatment (5d)
• Queensland researchers attempt 150-day vaccine challenge (5d)

Google News Biotech

• Injectable Male Birth Control Effective for at Least 2 Years, Says Biotech Startup - Gizmodo (10h)
• Wall Street’s New Tariff Safe Haven: High-Tax Biotech Stocks - WSJ (13h)
• Wall Street’s New Tariff Safe Haven: High-Tax Biotech Stocks - Yahoo Finance (13h)
• Korea Herald Roundtable for Pharma & Biotech - The Korea Herald (19h)
• Rossari Biotech Releases Q4 & FY25 Earnings Presentation - MSN (22h)
• Breakthrough Cancer Vaccine Technology Reveals New Approach to Reprogram Tumor Environment - Stock Titan (1d)
• BioSpectrum Asia picks top 3 pharma & biotech exhibitors at ICPI Week 2025 - BioSpectrum Asia (1d)
• STAT readers on the animal wellness industry, drug price floors, and more - statnews.com (1d)
• Biotech company AMGEN launching a major expansion - nbc4i.com (1d)
• Biotech Company Reports Promising Neurological Treatment in Clinical Study - streetwisereports.com (2d)
• National Security Commission on Emerging Biotechnology’s Final Report Includes Recommendations to Boost Economy and Protect National Security - NatLawReview.com (2d)
• Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today - MSN (2d)
• Biotech mogul Sam Waksal of Martha Stewart fame accused of testing illegal 'swine drug' on child - New York Post (2d)
• Pharma reshoring: Amgen invests $900M in Ohio biotech facility - Yahoo Finance (2d)
• Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today - The Motley Fool (2d)
• Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today - Yahoo Finance (2d)
• Biotech Firm Founder Buys Most of Tribeca Building for $32M - Commercial Observer (2d)
• New Albany biotech facility announces $900 million expansion - 10TV (2d)
• Biotech firm Amgen adding hundreds of jobs, plans $900M New Albany expansion - The Columbus Dispatch (2d)
• Amgen to expand Ohio biotech manufacturing plant - Reuters (2d)